FDA Draft Guidance Sparks Industry Comments on Generic Drug Pathways

PhRMA and AAM have submitted comments urging FDA to clarify parts of its August 2026 draft guidance on ANDA and 505(b)(2) submissions.

Updated on Nov. 17, 2026 in Biotech

FDA Draft Guidance Sparks Industry Comments on Generic Drug Pathways

The Food and Drug Administration's August 2026 draft guidance clarifies differences among abbreviated approval pathways and the data accepted for those applications. The Pharmaceutical Research and Manufacturers of America (PhRMA) and the Association for Accessible Medicines (AAM) have submitted comments recommending clarifications before the guidance replaces its 2019 predecessor.

Why it matters

The guidance shapes how generic and follow-on drug developers prove bioequivalence and safety, affecting the time and cost of bringing lower-cost medicines to market across the United States. Industry feedback on the scope of confirmatory studies and alternative bioequivalence methods could influence the final version.

The draft replaces a 2019 guidance and addresses how ANDA applicants may use confirmatory studies, which FDA says are not required to establish safety or effectiveness. Industry requests focus on bioequivalence methods when a reference listed drug is removed from the Orange Book, and on inactive ingredient criteria for parenteral, ophthalmic, and otic products; FDA's final decisions on these points remain unknown.

The players

Food and Drug Administration (FDA)

The U.S. federal agency responsible for regulating drugs, including the approval pathways for generic and follow-on medicines under the Hatch-Waxman framework.

Pharmaceutical Research and Manufacturers of America (PhRMA)

The main U.S. trade association representing brand-name pharmaceutical companies, which has long advocated for preserving distinct approval pathways.

Association for Accessible Medicines (AAM)

A trade association representing generic and biosimilar drug manufacturers that advocates for timely, affordable access to lower-cost medicines.

The details

PhRMA urged FDA to keep the longstanding distinction between the ANDA and 505(b)(2) pathways and to narrow the scope of limited confirmatory studies accepted in an ANDA. AAM asked FDA to clarify alternative bioequivalence methods and to broaden criteria allowing generic parenteral, ophthalmic, and otic products to use different inactive ingredients than the reference drug.

Timeline

  1. August 2026: FDA issues the draft guidance on ANDA and 505(b)(2) pathways.

  2. August 18: Regulatory Focus reports on the draft guidance's clarification of pathway differences.

  3. November 17, 2026: PhRMA and AAM comments are recorded in the stub as the core event.

Biotech Foundations

The draft guidance updates how FDA implements the ANDA and 505(b)(2) pathways created by the Hatch-Waxman Amendments of 1984, refining the data requirements that generic and follow-on developers must meet. It replaces the 2019 version and is now open to industry comment before finalization.

Generic drug developers will need to follow the final guidance when preparing ANDA and 505(b)(2) submissions, which can affect how quickly lower-cost medicines reach pharmacy shelves. Changes to bioequivalence and inactive ingredient requirements could influence the availability and cost of generic versions of certain injectable, eye, and ear medications.

The takeaway

Clear regulatory pathways determine how quickly affordable medicines reach patients, so the final wording of this guidance matters for both developers and consumers. Watching how FDA responds to these industry comments will show where the agency draws the line between flexibility and safety.

Further reading

For broader context on how regulators are shaping drug development, explore recent Biotech coverage.